OK From my perspective Enzon was fairly cash rich for a biotech before Icahn. When he came on board he asked the company to use their cash to buy back shares. While they did so, short interest increased and the share price dropped. Then when they had spent much of the cash they had, it was harder to fund research. There were a few special dividends to shareholders but they did not make up for the gutting of the company. And I believe China was involved somewhere along the line. Anyway if there's not a chance that Ambroxal is the target company going forward and the ENZN NOLS are not utilized then there should be really strong grounds for any existing ENZN shareholders to file a lawsuit if any are left.
Market Data 
Markets 
AI
